1. Medtech Insight
  2. >>Device Area
  3. >>Orthopedics

Stryker Says It's Not Chasing Boston Scientific

 
• By Tina Tan

Rumors of a potential Stryker-Boston Scientific coupling have been quashed after the orthopedics player officially stated it is not in discussions with the cardiology company.

Stryker Corp. has spoken out and confirmed it is not in discussions with Boston Scientific Corp. about a potential takeover bid. In quashing the rumors about a deal, Stryker's share price – which has been sliding over the two days of escalating speculation – has double backed and jumped up 6% to surpass $173 during trading on June 13, hours after the company issued its official statement.

Prior to Stryker's statement, the general consensus from analysts was that a Stryker-Boston Scientific combination – while certainly creating a company with significant product breadth – would not be a...

More from Orthopedics

More from Device Area

FDLI: Clinical Labs Face Uncertainty After Texas Court’s LDT Ruling

 
• By Elizabeth Orr

A Texas court's decision against US FDA regulation of lab-developed tests (LDTs) has introduced new uncertainties for clinical labs. Industry stakeholders are now worried about potential future regulations while also managing existing compliance requirements. Recent conference discussions underscored the complexities of FDA oversight.

Data Finds Capillary Blood Is A Reliable Alternative To Venous Blood For Routine Testing

 
• By Natasha Barrow

A study from Babson Diagnostics published in the peer-reviewed Journal of Applied Laboratory Medicine showed that capillary blood sample volume issues can overcome historical challenges, such as poor quality, through a technique called assay miniaturization.

First Alzheimer’s Disease Diagnostic Blood Test Cleared By FDA

 
• By Natasha Barrow

Fujirebio Diagnostics' Alzheimer's disease test, Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio, has been cleared by the US FDA.